Literature DB >> 23110942

Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis.

Muthusamy Thiruppathi1, Julie Rowin, Balaji Ganesh, Jian Rong Sheng, Bellur S Prabhakar, Matthew N Meriggioli.   

Abstract

Previous studies have reported alterations in numbers or function of regulatory T (Treg) cells in myasthenia gravis (MG) patients, but published results have been inconsistent, likely due to the isolation of heterogenous "Treg" populations. In this study, we used surface CD4, CD25(high), and CD127(low/-) expression to isolate a relatively pure population of Tregs, and established that there was no alteration in the relative numbers of Tregs within the peripheral T cell pool in MG patients. In vitro proliferation assays, however, demonstrated that Treg-mediated suppression of responder T (Tresp) cells was impaired in MG patients and was associated with a reduced expression of FOXP3 in isolated Tregs. Suppression of both polyclonal and AChR-activated Tresp cells from MG patients could be restored using Tregs isolated from healthy controls, indicating that the defect in immune regulation in MG is primarily localized to isolated Treg cells, and revealing a potential novel therapeutic target.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23110942      PMCID: PMC3501560          DOI: 10.1016/j.clim.2012.09.012

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  54 in total

1.  A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score.

Authors:  Donald B Sanders; Bernadette Tucker-Lipscomb; Janice M Massey
Journal:  Ann N Y Acad Sci       Date:  2003-09       Impact factor: 5.691

2.  Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion.

Authors:  C Bouneaud; P Kourilsky; P Bousso
Journal:  Immunity       Date:  2000-12       Impact factor: 31.745

3.  CD4+CD25high regulatory cells in human peripheral blood.

Authors:  C Baecher-Allan; J A Brown; G J Freeman; D A Hafler
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

Review 4.  Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.

Authors:  A Jaretzki; R J Barohn; R M Ernstoff; H J Kaminski; J C Keesey; A S Penn; D B Sanders
Journal:  Neurology       Date:  2000-07-12       Impact factor: 9.910

5.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

Review 6.  Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis.

Authors:  Eleonora Gambineri; Troy R Torgerson; Hans D Ochs
Journal:  Curr Opin Rheumatol       Date:  2003-07       Impact factor: 5.006

7.  Circulating CD4+CD25+ and CD4+CD25+ T cells in myasthenia gravis and in relation to thymectomy.

Authors:  Y-M Huang; R Pirskanen; R Giscombe; H Link; A-K Lefvert
Journal:  Scand J Immunol       Date:  2004-04       Impact factor: 3.487

Review 8.  Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.

Authors:  Shimon Sakaguchi
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

9.  Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood.

Authors:  H Jonuleit; E Schmitt; M Stassen; A Tuettenberg; J Knop; A H Enk
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

10.  Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

Authors:  T Takahashi; T Tagami; S Yamazaki; T Uede; J Shimizu; N Sakaguchi; T W Mak; S Sakaguchi
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

View more
  42 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Systemic lupus erythematosus-myasthenia gravis overlap syndrome: Presentation and treatment depend on prior thymectomy.

Authors:  Scott Brian Minchenberg; Geeta Chaparala; Zachary Oaks; Katalin Banki; Andras Perl
Journal:  Clin Immunol       Date:  2018-07-17       Impact factor: 3.969

Review 3.  Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.

Authors:  Grayson Beecher; Brendan Nicholas Putko; Amanda Nicole Wagner; Zaeem Azfer Siddiqi
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

Review 4.  B cells in the pathophysiology of myasthenia gravis.

Authors:  John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2017-09-30       Impact factor: 3.217

Review 5.  Regulatory T cells in the treatment of disease.

Authors:  Amir Sharabi; Maria G Tsokos; Ying Ding; Thomas R Malek; David Klatzmann; George C Tsokos
Journal:  Nat Rev Drug Discov       Date:  2018-10-12       Impact factor: 84.694

Review 6.  Functional defect in regulatory T cells in myasthenia gravis.

Authors:  Muthusamy Thiruppathi; Julie Rowin; Qin Li Jiang; Jian Rong Sheng; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

7.  LPS-treated bone marrow-derived dendritic cells induce immune tolerance through modulating differentiation of CD4+ regulatory T cell subpopulations mediated by 3G11 and CD127.

Authors:  Fang Zhou; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  Immunol Res       Date:  2017-06       Impact factor: 2.829

8.  Higher Frequency and Increased Expression of Molecules Associated with Suppression on T Regulatory Cells from Newborn Compared with Adult Nonhuman Primates.

Authors:  Beth C Holbrook; Martha A Alexander-Miller
Journal:  J Immunol       Date:  2020-09-02       Impact factor: 5.422

9.  Highly heterogeneous, activated, and short-lived regulatory T cells during chronic filarial infection.

Authors:  Simon Metenou; Yaya I Coulibaly; Daniel Sturdevant; Housseini Dolo; Abdallah A Diallo; Lamine Soumaoro; Michel E Coulibaly; Kishore Kanakabandi; Stephen F Porcella; Amy D Klion; Thomas B Nutman
Journal:  Eur J Immunol       Date:  2014-05-22       Impact factor: 5.532

10.  The effect of interleukin (IL)-21 and CD4+ CD25++ T cells on cytokine production of CD4+ responder T cells in patients with myasthenia gravis.

Authors:  M Alahgholi-Hajibehzad; H Durmuş; F Aysal; Y Gülşen-Parman; P Oflazer; F Deymeer; G Saruhan-Direskeneli
Journal:  Clin Exp Immunol       Date:  2017-07-28       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.